Wave Life Sci Ord Sh (WVE)

$6.27 0.39 (6.63%)

13:13 EDT WVE Stock Quote Delayed 30 Minutes

WVE Stock Earnings: WAVE Life Sciences Beats EPS, Beats Revenue for Q4 2023

By InvestorPlace Earnings Mar 6, 2024

WVE stock results show that WAVE Life Sciences beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

7 A-Rated Biotech Stocks for Your August Buy List

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

More Articles

Volume:

Previous Close -

Market Cap 620.63M

PE Ratio -13.34

EPS -0.47

Volume (Avg. Vol.) 399,027

Day's Range $5.90 - $6.38

52-Week Range $3.25 - $7.67

Dividend & Yield N/A (N/A)

WVE Stock Predictions, Articles, and Wave Life Sci Ord Sh News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Jun 24, 2022

It's time for the last breakdown of the biggest pre-market stock movers of the week as we look at what's happening Friday morning!

Wave Life Sciences News: WVE Stock Crashes 50% on Huntington’s Disease Data

By William White, InvestorPlace Writer Dec 30, 2019

Wave Life Sciences (WVE) news for Monday has WVE stock taking a beating on early data from its Huntington’s disease trial.

Wave Life Sciences News: WVE Stock Slammed 54% by Duchenne Drug Failure

By William White, InvestorPlace Writer Dec 16, 2019

Wave Life Sciences (WVE) news for Monday about it giving up on a Duchenne muscular dystrophy drug is hitting WVE stock hard.

BMO starts Korro at outperform, cites upcoming data for AATD drug (NASDAQ:KRRO)

From Seeking Alpha Feb 27, 2024

BMO initiated coverage of Korro Bio (KRRO) with an outperform rating, citing upcoming data for its AATD drug candidate KRRO-110 and potential partnerships. Read more here.

Sarepta Therapeutics Inc.: Why it's a rising gene therapy star

From MarketBeat Jan 23, 2024

Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases.

Mizuho says market 'doesn't understand' Wave capital raise (NASDAQ:WVE)

From Seeking Alpha Dec 8, 2023

Mizuho says the market "doesn't understand" the recent capital raise by Wave Life Sciences (WVE) that triggered a major selloff in the stock. Read more here.

Wave Life Sciences falls sharply on pricing $100M secondary offering (NASDAQ:WVE)

From Seeking Alpha Dec 7, 2023

Wave Life Sciences prices $100 million public offering of common shares at $5.00 per share, with an option for underwriters to purchase additional shares.

Mizuho Securities Remains a Buy on Wave Life Sciences (WVE)

From TipRanks Dec 12, 2022

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Wave Life Sciences (WVE – Research Report), with a price t...

SVB Securities Remains a Hold on Wave Life Sciences (WVE)

From TipRanks Nov 14, 2022

In a report released on November 10, Mani Foroohar from SVB Securities reiterated a Hold rating on Wave Life Sciences (WVE – Research Report), with a price ta...

ADVERTISEMENT